The combination of the corticosteroid fluticasone furoate (FF) and the long-acting beta-agonists Vilanteroltrifenatat (VT) Relovair ® (Glaxo SmithKline / Theravance) now for the once-daily inhaled Treatment in asthma patients in a Phase III trial program tested. is inhaled
the new combination FF / VT on a novel single-dose applicator.
The program consists of eight studies. The Phase III trials of COPD program started in 2009.
0 comments:
Post a Comment